Literature DB >> 10604967

Effect of intrathecal nocistatin on the formalin-induced pain in mice versus that of nociceptin/orphanin FQ.

H Nakano1, T Minami, K Abe, T Arai, M Tokumura, N Ibii, E Okuda-Ashitaka, H Mori, S Ito.   

Abstract

The effect of intrathecal nocistatin on formalin-induced pain in mice was investigated and compared with that of nociceptin/orphanin FQ (Noc/OFQ) to get information on the functional relationship between nocistatin and Noc/OFQ in the spinal cord. Subcutaneous injection of formalin into the hindpaw induced biphasic pain behaviors. Nocistatin, 1 pg, given intrathecally 1 min before 2% formalin injection, significantly attenuated the first phase of the formalin-induced pain. Also, 10 to 1000 pg of nocistatin, given 10 min after formalin injection, significantly inhibited the second phase of the formalin test. Naloxone, 5 mg/kg i.p., failed to antagonize inhibitory effects of nocistatin on either phase of the formalin-induced pain, indicating that analgesic effects of nocistatin were unrelated to the classic opioid system. At 1 to 100 pg, Noc/OFQ exerted no influence on either phase of the 2% formalin-induced pain. However, at 1% formalin, Noc/OFQ significantly aggravated the second phase at 10 pg but not the first phase at 1 to 1000 pg. This aggravating effect of Noc/OFQ was completely reversed by 10 pg of nocistatin. At 0.3 and 1 microg, Noc/OFQ, but not nocistatin, significantly inhibited both phases of the 2% formalin-induced pain. Suppressive effects of 1 microg of Noc/OFQ on the formalin-induced pain were not affected by 1 microg of nocistatin. These results suggest that Noc/OFQ might be involved in the second phase of the mouse formalin test and that, under such pathophysiological conditions, nocistatin could exhibit antagonism against Noc/OFQ at the spinal level.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10604967

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Identification of NIPSNAP1 as a nocistatin-interacting protein involving pain transmission.

Authors:  Emiko Okuda-Ashitaka; Toshiaki Minami; Shingo Tsubouchi; Hiroshi Kiyonari; Akihiro Iwamatsu; Tetsuo Noda; Hiroshi Handa; Seiji Ito
Journal:  J Biol Chem       Date:  2012-02-06       Impact factor: 5.157

2.  Control of glutamate and GABA release by nociceptin/orphanin FQ in the rat lateral amygdala.

Authors:  S Meis; H C Pape
Journal:  J Physiol       Date:  2001-05-01       Impact factor: 5.182

3.  Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice.

Authors:  T Minami; H Nakano; T Kobayashi; Y Sugimoto; F Ushikubi; A Ichikawa; S Narumiya; S Ito
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

4.  Pharmacological properties of nociceptin/orphanin FQ-induced stimulation and inhibition of cyclic AMP formation in distinct layers of rat olfactory bulb.

Authors:  Maria C Olianas; Pierluigi Onali
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

5.  Nocistatin sensitizes TRPA1 channels in peripheral sensory neurons.

Authors:  Luca Avenali; Oli Abate Fulas; Julia Sondermann; Pratibha Narayanan; David Gomez-Varela; Manuela Schmidt
Journal:  Channels (Austin)       Date:  2016-06-30       Impact factor: 2.581

6.  Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test.

Authors:  Elaine C Gavioli; Giles A Rae; Girolamo Calo'; Remo Guerrini; Thereza C M De Lima
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

7.  Involvement of NIPSNAP1, a neuropeptide nocistatin-interacting protein, in inflammatory pain.

Authors:  Kazuya Okamoto; Masaki Ohashi; Kana Ohno; Arisa Takeuchi; Etsuko Matsuoka; Kyohei Fujisato; Toshiaki Minami; Seiji Ito; Emiko Okuda-Ashitaka
Journal:  Mol Pain       Date:  2016-03-10       Impact factor: 3.395

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.